Literature DB >> 20345346

Antibodies in single-chain format against tumour-associated antigens: present and future applications.

L Accardi1, P Di Bonito.   

Abstract

The recombinant antibodies in single-chain format (scFv) have found broad applications in both therapeutic and diagnostic fields. Tumour-associated antigens (TAAs) are proteins or other molecular species expressed in a specific tumour type, that can be targeted for diagnostic and immunotherapy purposes. The possibility of obtaining highly selective and efficacious scFvs makes them appropriate tools to target TAAs. The approach utilised for targeting depends on the nature of TAAs and their cell localisation. Tumour antigens displayed on the cell surface can be recognised by scFvs coupled to radioisotopes, toxins and enzymes to be used in cancer diagnosis and therapy. Intracellular tumour antigens can be targeted by scFvs expressed as "intracellular antibodies". This review reports the existing scFv-based formats, hints of their generation and pharmacokinetics, and a description of the most promising TAAs. It also provides an update of in vitro, preclinical and clinical studies using scFvs against TAAs for cancer diagnosis and treatment, with their merits and limits.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20345346     DOI: 10.2174/092986710791111215

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  10 in total

1.  Anti-CHMP5 single chain variable fragment antibody retrovirus infection induces programmed cell death of AML leukemic cells in vitro.

Authors:  Hai-rong Wang; Zhen-yu Xiao; Miao Chen; Fei-long Wang; Jia Liu; Hua Zhong; Ji-hua Zhong; Ren-rong Ou-Yang; Yan-lin Shen; Shu-ming Pan
Journal:  Acta Pharmacol Sin       Date:  2012-05-21       Impact factor: 6.150

2.  Triple blockade of HER2 by a cocktail of anti-HER2 scFv antibodies induces high antiproliferative effects in breast cancer cells.

Authors:  Foroogh Nejatollahi; Mansooreh Jaberipour; Mahdi Asgharpour
Journal:  Tumour Biol       Date:  2014-05-15

3.  Retinoblastoma-independent antiproliferative activity of novel intracellular antibodies against the E7 oncoprotein in HPV 16-positive cells.

Authors:  Luisa Accardi; Maria Gabriella Donà; Anna M Mileo; Marco G Paggi; Antonio Federico; Paola Torreri; Tamara C Petrucci; Rosita Accardi; David Pim; Massimo Tommasino; Lawrence Banks; Barbara Chirullo; Colomba Giorgi
Journal:  BMC Cancer       Date:  2011-01-17       Impact factor: 4.430

4.  Rationalization and design of the complementarity determining region sequences in an antibody-antigen recognition interface.

Authors:  Chung-Ming Yu; Hung-Pin Peng; Ing-Chien Chen; Yu-Ching Lee; Jun-Bo Chen; Keng-Chang Tsai; Ching-Tai Chen; Jeng-Yih Chang; Ei-Wen Yang; Po-Chiang Hsu; Jhih-Wei Jian; Hung-Ju Hsu; Hung-Ju Chang; Wen-Lian Hsu; Kai-Fa Huang; Alex Che Ma; An-Suei Yang
Journal:  PLoS One       Date:  2012-03-22       Impact factor: 3.240

5.  A novel intracellular antibody against the E6 oncoprotein impairs growth of human papillomavirus 16-positive tumor cells in mouse models.

Authors:  Carla Amici; Michela Visintin; Francesca Verachi; Francesca Paolini; Zulema Percario; Paola Di Bonito; Angela Mandarino; Elisabetta Affabris; Aldo Venuti; Luisa Accardi
Journal:  Oncotarget       Date:  2016-03-29

6.  Purification and Characterization of Antibodies in Single-Chain Format against the E6 Oncoprotein of Human Papillomavirus Type 16.

Authors:  F Verachi; Z Percario; P Di Bonito; E Affabris; C Amici; L Accardi
Journal:  Biomed Res Int       Date:  2018-05-20       Impact factor: 3.411

Review 7.  Cancer Cell Glycocalyx and Its Significance in Cancer Progression.

Authors:  Hongyan Kang; Qiuhong Wu; Anqiang Sun; Xiao Liu; Yubo Fan; Xiaoyan Deng
Journal:  Int J Mol Sci       Date:  2018-08-22       Impact factor: 5.923

8.  Intrabodies targeting human papillomavirus 16 E6 and E7 oncoproteins for therapy of established HPV-associated tumors.

Authors:  Francesca Paolini; Carla Amici; Mariantonia Carosi; Claudia Bonomo; Paola Di Bonito; Aldo Venuti; Luisa Accardi
Journal:  J Exp Clin Cancer Res       Date:  2021-01-23

9.  ScFv anti-heparan sulfate antibodies unexpectedly activate endothelial and cancer cells through p38 MAPK: implications for antibody-based targeting of heparan sulfate proteoglycans in cancer.

Authors:  Helena C Christianson; Toin H van Kuppevelt; Mattias Belting
Journal:  PLoS One       Date:  2012-11-09       Impact factor: 3.240

10.  Generation of recombinant antibodies to rat GABAA receptor subunits by affinity selection on synthetic peptides.

Authors:  Sujatha P Koduvayur; Hélène A Gussin; Rajni Parthasarathy; Zengping Hao; Brian K Kay; David R Pepperberg
Journal:  PLoS One       Date:  2014-02-19       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.